A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumor cells has shown promise in patients with six different cancer types.
In patients with advanced, drug-resistant cancers, over a quarter with cervical and bladder tumors, and nearly 15 per cent with ovarian and lung tumors, responded to the new treatment.
The innovative new drug, called tisotumab vedotin (or TV for short), releases a toxic substance to kill cancer cells from within. The results have been so positive the drug has now moved forward to phase II trials in cervical cancer and will be tested in a range of additional solid tumor cancers.
They saw responses in 27 per cent of patients with bladder cancer, 26.5 per cent with cervical cancer, 14 per cent ovarian cancer, 13 per cent with oesophageal, 13 per cent with non-small cell lung and 7 per cent with endometrial cancer (although not in any men with prostate cancer).
TV is now being trialed in other cancer types including bowel, pancreatic, squamous cell lung and head and neck, as well as in a phase II trial as a second-line treatment for cervical cancer.
Read full, original post: New cancer drug that acts as ‘Trojan horse’ shows promise in patients with various cancers